Author

P. Penaloza-MacMaster

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 7 Bioengineering· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 9 Organism:mouse· 7 Research Focus:drug response / drug discovery· 6 Organism:human· 4 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1

Frequent Co-Authors

T. Dangi· 7 shared S. Sanchez· 5 shared J. Class· 3 shared J. M. Richner· 3 shared N. Palacio· 3 shared B. Awakoaiye· 2 shared B. Tian· 2 shared E. B. Chang· 2 shared

Activity by Year

2020-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

T. Dangi

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Time-dependent enhancement of mRNA vaccines by 4-1BB costimulation

S. Sanchez, T. Dangi, B. Awakoaiye, N. Irani, S. Fourati, J. M. Richner, P. Penaloza-MacMaster

This study shows that administering 4-1BB costimulatory antibodies after 96 hours post-mRNA vaccination enhances CD8 T cell responses and protection against breakthrough infections.

bioRxiv · Mar 1, 2024 · PreprintImmunology

Replication-attenuated r3LCMV vectors potentiate tumor control via IFN-I

Y. R. Chung, B. Awakoaiye, T. Dangi, S. Fourati, P. Penaloza-MacMaster

This study shows that replication-attenuated r3LCMV vectors enhance tumor control and survival in multiple tumor models, including immunodeficient mice, through IFN-I signaling.

bioRxiv · Dec 8, 2023 · PreprintImmunology

Pre-existing immunity modulates responses to mRNA boosters

T. Dangi, S. Sanchez, M. H. Lew, L. Visvabharathy, J. M. Richner, I. Koralnik, P. Penaloza-MacMaster

The paper shows pre-existing immunity affects the effectiveness of mRNA vaccine boosters, with lower pre-existing antibodies leading to greater post-booster increases and updated vaccines being more effective in certain serostatus groups.

bioRxiv · Jun 27, 2022Immunology

Nucleocapsid-specific humoral responses improve the control of SARS-CoV-2

T. Dangi, S. Sanchez, M. Park, J. Class, M. C. Richner, J. M. Richner, P. Penaloza-MacMaster

This study shows that nucleocapsid-specific antibodies can help control SARS-CoV-2 infection in mice, suggesting their potential inclusion in vaccines and monoclonal therapies.

bioRxiv · Mar 9, 2022 · PreprintImmunology

SARS coronavirus vaccines protect against different coronaviruses

T. Dangi, N. Palacio, S. Sanchez, J. Class, L. Visvabharathy, T. Ciucci, I. Koralnik, J. Richner, P. Penaloza-MacMaster

This study shows SARS-CoV-2 vaccines and prior coronavirus infections generate cross-reactive antibodies and T cell responses that provide protection against other coronaviruses in humans and mice.

bioRxiv · Jun 1, 2021 · PreprintImmunology

A SARS CoV-2 nucleocapsid vaccine protects against distal viral dissemination

J. Class, T. Dangi, J. Richner, P. Penaloza-MacMaster

This study shows that including the nucleocapsid antigen in SARS CoV-2 vaccines improves protection against viral spread to the brain.

bioRxiv · Apr 26, 2021 · PreprintImmunology

Limiting the priming dose of a SARS CoV-2 vaccine improves virus-specific immunity

S. Sanchez, N. Palacio, T. Dangi, T. Ciucci, P. Penaloza-MacMaster

This study shows that reducing the priming dose of a SARS-CoV-2 vaccine can lead to stronger immune responses after boosting, suggesting potential benefits for vaccine distribution and design.

bioRxiv · Mar 31, 2021 · PreprintImmunology

Nanotraps for the containment and clearance of SARS-CoV-2

M. Chen, J. Rosenberg, X. Cai, A. C. H. Lee, J. Shi, M. Nguyen, T. Wignakumar, V. Mirle, A. J. Edobor, J. Fung, J. S. Donington, K. Shanmugarajah, E. B. Chang, G. Randall, P. Penaloza-MacMaster, , J. Huang

This paper introduces Nanotraps, functionalized nanoparticles that block SARS-CoV-2 infection by inhibiting spike protein-ACE2 interaction and triggering macrophage-mediated viral clearance.

bioRxiv · Feb 1, 2021Bioengineering

Targeting Scavenger Receptor Type B-1 (SR-B1) and Cholesterol Inhibits Entry of SARS-CoV-2 Pseudovirus in Cell Culture

S. E. Henrich, K. M. McMahon, N. Palacio, P. Bhalla, P. Penaloza-MacMaster, C. S. Thaxton

This study shows that targeting SR-B1 with cholesterol-poor HDL nanoparticles inhibits SARS-CoV-2 pseudovirus entry in human cells.

bioRxiv · Dec 14, 2020 · PreprintMicrobiology

A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2

X. Cai, A. Prominski, Y. Lin, N. Ankenbruck, J. Rosenberg, M. Chen, J. Shi, E. B. Chang, P. Penaloza-MacMaster, B. Tian, J. Huang

This paper develops a photothermal nanoparticle conjugated with neutralizing antibodies to capture and inactivate SARS-CoV-2, showing efficient viral capture, photothermal effect, and inhibition of viral entry.

bioRxiv · Nov 30, 2020 · PreprintBioengineering